Transcriptomic "portraits" of canine mammary cancer cell lines with various phenotypes

Journal of Applied Genetics

Volumn 51, Issue 2, 2010, Pages 169-183

  Krol M ^a   Pawlowski K M ^a   Skierski, J ^b   Turowski, P ^c   Majewska, A ^a   Polanska J ^d   Ugorski, M ^d,e   Morty, R E ^c   Motyl, T ^a  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^e INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Canine mammary cancer cells; DNA microarray; Transcriptomics

Indexed keywords

CANIS FAMILIARIS;

EID: 77952813730     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03195725     Document Type: Article

References (40)

1. Allison DB, 2002. Statistical methods for microarray research for drug target identification. Proc Soc Stat Sect 37-44.
2. Brinkhof B, Spee B, Rothuizen J, Penning LC, 2006. Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 356: 36-43.
3. Chopin LK, Jeffery PL, Yeh A, McNamara JF, Wight R, Herington AC, 2005. Ghrelin and hormone-dependent cancer. Proc Aust Physiol Pharmacol Soc.
4. Christensen CN, Ambartsumian G, Gilestro B, et al. 2005. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. Cancer Res 65: 6167-6177.
5. D'Amours D, Amon A, 2004. At the interface between signaling and executing anaphase-Cdc14 and the FEAR network. Genes Dev 18: 2581-2595.
6. Darzynkiewicz Z, Robinson JP, Crissman HA, 1994. Methods in cell biology. Flow cytometry, 2nd ed. Part A. San Diego, California: Academic Press. 41: 211-217, 409-410.
7. Donnenberg V, Donnenberg A, 2005. Multiple drug resistance in cancer revisited: the cancer stem cells hypothesis. J Clin Pathol 45: 872-877.
8. Eisen MB, Spellman PT, Brown PO, Botstein D, 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA95:14863-14868.
9. Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A, Sterner-Kock A, 2006. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet Pathol 43: 934-942.
10. Gebre-Medhin M, Kindlom LG, Wennbo H, Tornell J, Meis-Kindblom JM, 2001. Growth hormone receptor is expressed in human breast cancer. Am J Pathol 158: 1217-1222.
11. Hellmen E, 1992. Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines. In Vitro Cell Dev Biol 28A: 309-319.
12. Hellmen E, Moller M, Blankenstein MA, Andersson L, Westermark B, 2000. Expression of different phe-notypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. Breast Cancer Res Treat 61: 197-210.
13. Jeffrey PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, et al. 2005. Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer 12: 839-850.
14. KeeshanK, Mills KI, Cotter TG, McKenna SL, 2001. Elevated Bcr-Abl expression levels are sufficient fora haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 15: 1823-1833.
15. Kendziorski CM, Zhang Y, Lan H, Attie AD, 2003. The efficiency of pooling mRNA in microarray experiments, Biostatistics 4,3: 465-477.
16. Kendziorski CM, Irizarry RA, Chen KS, Haag JD, Gould MN, 2005. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad SciUSA 102: 124252-124257.
17. Król M, Pawłowski KM, Otrsjbska D, Motyl T, 2009a. DNA microarrays - future in oncology. JCPCR 2: 091-096.
18. Król M, Pawlowski KM, Motyl T, 2009b. Mikromacierze DNA w onkologii weterynaryjnej [DNA microarrays in veterinary oncology]. Medycyna Weterynaryjna 65: 376-380.
19. Król M, Pawłowski KM, Skierski J, Rao NAS, Hellmen E, Mol JA, Motyl T, 2009c. Transcriptomic profile of two canine cancer cell lines with different proliferative and anti-apoptotic potential. J Physiol Pharmacol 60: 95-106.
20. Król M, Polańska J, Pawłowski KM, Turowski P, Skierski J, Majewska A, et al. 2010. Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs. J Appl Genet 51: 37-50.
21. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. 2005. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819.
22. Macoska JA, 2002. The progressing clinical utility of DNA microarrays. CA Cancer J Clin 52: 50-59.
23. Madej JA, Rotkiewicz T 2006. Patologia ogólna zwierza̧t (General animal pathology). Olsztyn: Uniwersytet Warmińskio-Mazurski.
24. Misdorp W, 2002. Tumors of the mammary gland. In: Tumors in domestic animals, 4th ed., Iowa State Press, Blackwell Publ. Comp. 589-602.
25. Misher H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, et al. 2005. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 33: 284-288.
26. Oshlack A, Emsile D, Corcoran LM, Smyth GK, 2007. Normalization of boutique two-color microarrays with a high proportion of differentially expressed probes. Genome Biol 8:R2.
27. Ougolkov AV, Billadeau DD, 2006. Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2: 91-100.
28. Pawłowski KM, Król M, Majewska A, Badowska-Kozakiewicz A, Mol JA, Malicka E, Motyl T, 2009. Comparison of cellular and tissue transcriptomic profiles in canine mammary tumor. J Physiol Pharmacol 60: 85-94.
29. Ramaswamy S, Ross KN, Lander ES, Golub TR, 2002. A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
30. Rao NAS, van Wolferen ME, Gracanin A, Bhatti SFM, Król M, Holstege FC, Mol JA, 2009. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 60: 73-84.
31. Rao NAS, van Wolferen ME, van der Ham R, van Leenen D, Groot Koerkamp MJA, Holstege FCP, Mol JA, 2008. cDNA microarray profiles of canine mammary tumor cell lines reveal deregulated pathways pertaining to their phenotype. Anim Genet 39: 333-345.
32. Rolny C, Capparuccia L, Casazza A, etal. 2008. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med 205: 1155-1171.
33. Rutteman GR, Cornelisse CJ, Dijkshoorn NJ, Poortman J, Misdorp W, 1988. Flow cytometric analysis of DNA ploidy in canine mammary tumors, Cancer Res 48: 3411-3417.
34. Sobczak-Filipiak M., Malicka E., 2005. Estrogen receptors in canine mammary gland tumours. Pol J Vet Sci 5: 1-5.
35. Spee B., Jonkers MDB, Arends B, Rutteman GR, Rothuizen J., Penning LC, 2006. Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer 5:34.
36. Sterrenburg E, Turk R, Boer JM, van Ommen GB, den Dunnen JT, 2002. A common reference for cDNA microarray hybridizations. Nucleic Acids Res 30: 116.
37. Suyama E, Wadowa R, Kaur K, et al. 2006. Identification of metastasis-related genes in a mouse model using a library of randomized ribozymes. J Biol Chem 281: 18264.
38. Tusher VG, Tibshirani R, Chu G, 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad SciUSA98: 5116-5121.
39. Wagner K, Hemminki K, Grzybowska E, Klaes R, Burwinkel B, Bugert P, et al. 2006. Polymorphisms in genes involved in GH1 release and their association with breast cancer risk. Carcinogenesis 27: 1867-1875.
40. Veer LJ van't, Dai H, Vijver MJ van de, He YD, Hart AA, Peterse HL, etal. 2002. Gene expressionprofil-ing predicts clinical outcome of breast cancer. Nature 415: 530-536.